Business Essentials for Professionals

Pilot Delivery Program In US To Be Launched By Pfizer For Its Covid-19 Vaccine


Pilot Delivery Program In US To Be Launched By Pfizer For Its Covid-19 Vaccine
With the aim of identifying and addressing the delivery and distribution challenges for its ultra-cold storage requirements, a pilot delivery program for its experimental Covid-19 vaccine has been launched by the United States based drug maker Pfizer Inc in four US states.
The temperature requirements for the Covid-19 vaccine from Pfizer, which the company claimed has shown that it is more than 90 per cent effective in preventing Covid-19 infections based on interim last stage trial data, is extreme and required holders to be at more than -70 degrees Celsius which is significantly lower than the standard temperature requirement for vaccines at between 2 and -8 degrees Celsius.
“We are hopeful that results from this vaccine delivery pilot will serve as the model for other U.S. states and international governments, as they prepare to implement effective COVID-19 vaccine programs,” Pfizer said in a statement.
After considering the data on the differences in overall size, diversity of populations, the existing infrastructure for immunization, and the need to delivering the vaccine to individuals in varied urban and rural settings, the company has picked Rhode Island, Texas, New Mexico, and Tennessee for the pilot program.
Pfizer said that launching the pilot phase does not mean that the four selected US states will get the vaccine before the rest of eth country and there will also be no preferential treatment of the states in this regards.
It is expected that by the third week of November, the company will have enough safety data on the vaccine from currently ongoing large scale late-stage trials, following which it would start proceedings for applying for emergency use authorization (EUA), Pfizer said.
Under a $1.95 billion deal with the US government, Pfizer and its partner BioNTech will have to supply 100 million doses of the vaccine to the government with the later having the option to acquire an additional 500 million doses.
In another development in the run to the development of a Covid-19 vaccine, another US drug maker and Pfizer rival Moderna Inc also announced that its Covid-19 vaccine candidate has shown that is can prevent 94.5 per cent of infections of the novel coronavirus based on its interim data from a late-stage trial. That has also raised hopes that a vaccine against the disease could be available in the market soon.
A new technology called synthetic messenger RNA that helps to activate the human immune system to fight against the virus has been used by both Pfizer and Moderna for developing their vaccines.